ArticleFrontiers in genetics2025
Integrative analysis of DNA methylation, RNA sequencing, and genomic variants in the cancer genome atlas (TCGA) to predict endometrial cancer recurrence.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrating artificial intelligence and multi-omics data for precision oncology in endometrial cancer: a narrative review.Functional & integrative genomics · 2026Review
- From toxicogenomics to predictive toxicology and exposomics: defining the next decade of gene-environment research.Frontiers in genetics · 2026Article
- Application of explainable artificial intelligence integrating with electronic health record in oncology.Exploration of targeted anti-tumor therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The prognosis within each subtype varies due to histological and molecular factors. This study leverages omics datasets and machine learning to identify biomarkers associated with EC recurrence in different molecular subtypes. Methods: Utilizing DNA methylation, RNA-sequencing, and common variant data from 116 EC samples in The Cancer Genome Atlas (TCGA), differentially expressed genes (DEGs) and differentially methylated regions (DMRs) were identified using t-tests between recurrence and non-recurrence groups. These were visualized through volcano plots and heat maps, while decision trees and random forests classified and stratified the samples. Results: A machine learning analysis combined with box plots showed that in the copy number-high (CN-H) recurrence group, PARD6G-AS1 had decreased methylation, CSMD1 had increased methylation, and TESC expression was higher than the non-recurrence group. In the copy number-low (CN-L) recurrence group, CD44 expression was elevated. Further validation using TCGA clinical data confirmed PARD6G-AS1 hypomethylation and CD44 overexpression as significant indicators of recurrence (p=0.006 and p=0.02, respectively), and both were linked to advanced stage and lymph node metastasis. Conclusion: The study concludes that PARD6G-AS1 hypomethylation and CD44 overexpression are potential predictors of recurrence in CN-H and CN-L EC patients, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.